Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity

Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity

The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).

Randomized controlled trial comparing efficacy of magnesium preloading versus normal saline for prevention of acute and chronic nephrotoxicity of cisplatin.

Inclusion Criteria:

• Age > 18 years
• Eastern Cooperative Oncology Group score 0-2
• First Diagnosed Head and neck cancer and plan for treatment with cisplatin
• Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2)

Exclusion Criteria:

• Prior treatment with cisplatin before randomization
• Uncontrolled concurrent disease
• Pregnancy